Chen H.-Y.TUN-JUN TSAI2020-12-242020-12-2420061016-7390https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750597307&partnerID=40&md5=cc3708ad116bc026c169b20efa78fd75https://scholars.lib.ntu.edu.tw/handle/123456789/532356Dyslipidemia is a common problem in chronic kidney disease (CKD) patients. According to the definitions of dyslipidmia published in ATP III (Adult Treatment Panel III), there are more than two-third CKD patients have this problem. The characteristics of dyslipidemia in CKD patients are low serum HDL and elevated serum triglyceride, VLDL and small dense LDL which are different from those in general population. The dyslipidemia may be induced by increased hepatic synthesis of VLDL lipoprotein, decreased HDL synthesis and the abnormality in lipoprotein metabolism caused by altered enzymatic activity. Dyslipidemia in CKD patients has been known to be a major risk factor of their cardiovascular disease, and may contribute to progressive renal dysfunction. Consequently, the K/DOQI proposed a therapeutic guideline for dyslipidemia In CKD patients and recommended the HMG-CoA reductase inhibitor as the drug of choice for them. We also presented a retrospective cohort of dialysis patients with dyslipidemia during 9 months period (from February 2004 to October 2004) in NTUH and gave some clinical examples for trouble-shooting and sharing experience.Chronic kidney disease; Dyslipidemia; HMG-CoA reductase inhibitor[SDGs]SDG3atorvastatin; azathioprine; bile acid sequestrant; cholesterol ester transfer protein; everolimus; fibric acid derivative; fluindostatin; gemfibrozil; high density lipoprotein; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein; macrolide; mevinolin; mycophenolic acid 2 morpholinoethyl ester; phosphatidylcholine sterol acyltransferase; pravastatin; simvastatin; triacylglycerol; tsukubaenolide; very low density lipoprotein; article; cardiovascular disease; chronic kidney disease; cohort analysis; dialysis; diet therapy; disease course; drug choice; dyslipidemia; enzyme activity; hemodialysis patient; human; kidney failure; lifestyle; lipoprotein blood level; lipoprotein metabolism; lipoprotein synthesis; practice guideline; retrospective study; risk factor; triacylglycerol blood leveljournal article2-s2.0-33750597307